- TG Therapeutics (TGTX +10.4%) jumps after announcing the initiation of a Phase 1 trial to test the efficacy and safety of a TG-1101/ TGR-1202 combo in relapsed and/or refractory CLL and NHL.
- In other company news, TGTX opens the first expansion cohort in a TGR-1202 dose escalation study — no MTD has yet been determined. (PR)
TG Therapeutics initiates study of ublituximab/ PI3K Delta inhibitor combo
Nov 25 2013, 14:11 ET